Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

By afschroeder • January 17, 2026

Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB. Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2026 Jan 2;9(1):e2551231. doi: 10.1001/jamanetworkopen.2025.51231. PMID: 41543856; PMCID: PMC12811811.

Tags: Hematology/Oncology, Publications, Veterans Administration

Related Posts

The evolving role of ctDNA in colorectal cancer: guidance of adjuvant therapy or surveillance strategies?

Barrett LG, Gangi A, Hendifar A, Osipov A, Atkins K, Zaghiyan K, Nasseri Y, Murrell Z, Waters K, Mehta P, Zell JA, Hitchins MP, Gong[...]

Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight

Kim KJ, Zhong H, Tai D, Shah P, Park D, Goes V, Li J, Jung C, Kim L, Guzman S, Brar G, Castillo D. Microbiome[...]

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL

O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin[...]